NCT03100591

A Study to Evaluate ACT-132577 in Healthy Male Subjects

Single-center, Open-label Study With 14C-radiolabeled ACT-132577 to Investigate the Mass Balance, Pharmacokinetics, and Metabolism Following Single Oral Administration to Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Idorsia Pharmaceuticals Ltd. · Industry
• Sex: Male
• Age: 45 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The primary purpose of this study is to investigate the rate and routes (urine and feces) of elimination of ACT-132577, and the mass balance in urine and feces

Conditions

• Healthy Subjects

Interventions

Type	Name	Description
DRUG	14C-radiolabeled ACT-132577	Single oral dose of 3.7 megabecquerel (MBq) (100 microcurie \[μCi\]) 14C-radiolabeled ACT-132577 administered as 1 capsule of 25 mg

Timeline

• Start date: 2017-03-28
• Primary completion: 2017-04-18
• Completion: 2017-04-18
• First posted: 2017-04-04
• Last updated: 2022-11-29

Locations

1 site across 1 country: Netherlands